The purpose of this study is to evaluate the effectiveness and safety of a home based infusion device for the delivery of a subcutaneous (under the skin) diuretic (Furoscix) in patients with chronic heart failure and fluid overload.

Balance is a double blind, placebo controlled phase 3 study of Akcea-APOCIII-LRX administered subcutaneously to patients with familial chylomicronemia syndrome (FCS).

Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant (CLEAR).

COORDINATE-Diabetes is a cluster-randomized clinical trial testing the effectiveness of an innovative, clinic level intervention to improve the management of type 2 Diabetes in patients with cardiovascular disease.

The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in patients initially presenting to the emergency department.

This study will compare a non-invasive point of care test developed using surface electrodes (like an EKG) and machine learning and signal analytics (artificial intelligence) to transform early detection of heart disease.

A Prospective, non-randomized, single-arm, international multicenter, clinical safety and effectiveness of a leadless pacemaker system in patients who are indicated for a VVIR pacemaker.

The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study.

The purpose of this extension study is to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study will be a global multicenter study.